$450~ would also be a good sign true.
I just saw this update on their LinkedIn and it's made me re-think my position, perhaps even a time to buy now.
A $20M valuation, minus the COH and you have basement level prices for a company with regulatory approved medical devices generating revenues in excess of $1M pa. Very strong clinical safety profile, a number of 'clinical firsts' (long bone, dental etc) and strong partnerships with reputable institutions and the share price just doesn't make sense.
Additionally, seeing this collaboration with Zimmer Biomet & DePuy is a very positive sign, these big boys are very accustomed to acquisitions/distribution.
Video Link:
Ann: OSX Enter Oral & Maxillofacial Market in Australia & NZ, page-7
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
